The balance of benefits and risks of aspirin in primary prevention is far less clear than in secondary prevention; further data from randomized trials of individuals at intermediate cardiovascular risk are needed. Decisions about aspirin in primary prevention should be made on a case-by-case basis, and general guidelines are not justified.

Original publication

DOI

10.1038/nrcardio.2012.26

Type

Journal article

Journal

Nat Rev Cardiol

Publication Date

28/02/2012

Volume

9

Pages

262 - 263

Keywords

Aspirin, Cardiovascular Diseases, Cyclooxygenase Inhibitors, Humans, Primary Prevention, Risk Factors